VIMTALABS

Vimta Labs Share Price

₹845.45 -43.7 (-4.91%)

22 Jan, 2025 12:18

SIP TrendupStart SIP in VIMTALABS

Start SIP

Performance

  • Low
  • ₹837
  • High
  • ₹879
  • 52 Week Low
  • ₹418
  • 52 Week High
  • ₹1,070
  • Open Price₹879
  • Previous Close₹889
  • Volume47,060

Investment Returns

  • Over 1 Month -12.11%
  • Over 3 Month + 50.2%
  • Over 6 Month + 66.53%
  • Over 1 Year + 89.12%
SIP Lightning

Smart Investing Starts Here Start SIP with Vimta Labs for Steady Growth!

Invest Now

Vimta Labs Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 37.6
  • PEG Ratio
  • 1.8
  • Market Cap Cr
  • 1,878
  • P/B Ratio
  • 5.5
  • Average True Range
  • 55.14
  • EPS
  • 24.04
  • Dividend Yield
  • 0.2
  • MACD Signal
  • 5.34
  • RSI
  • 45.99
  • MFI
  • 44.13

Vimta Labs Financials

Vimta Labs Technicals

EMA & SMA

Current Price
₹845.45
-43.7 (-4.91%)
pointer
  • stock-down_img
  • Bearish Moving Average 11
  • stock-up_img
  • Bullish Moving Average 5
  • 20 Day
  • ₹917.37
  • 50 Day
  • ₹873.86
  • 100 Day
  • ₹780.17
  • 200 Day
  • ₹674.92

Resistance and Support

884.62 Pivot Speed
  • R3 995.93
  • R2 957.32
  • R1 923.23
  • S1 850.53
  • S2 811.92
  • S3 777.83

What's your outlook on Vimta Labs?

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Vimta Labs Ltd. offers a wide range of testing, inspection, and analytical services, specializing in pharmaceuticals, food, and environmental testing. Serving clients globally, it provides high-quality, accredited lab services to ensure product safety and regulatory compliance.

Vimta Labs has an operating revenue of Rs. 327.86 Cr. on a trailing 12-month basis. An annual revenue de-growth of 0% needs improvement, Pre-tax margin of 17% is great, ROE of 12% is good. The company has a reasonable debt to equity of 3%, which signals a healthy balance sheet. The stock from a technical standpoint is trading below to its 50DMA and around 39% up from its 200DMA. It needs to take out the 50DMA levels and stay above it to make any further meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 88 which is a GOOD score indicating consistency in earnings, a RS Rating of 92 which is GREAT indicating the outperformance as compared to other stocks, Buyer Demand at A+ which is evident from recent demand for the stock, Group Rank of 62 indicates it belongs to a poor industry group of Medical-Services and a Master Score of B is close to being the best. Overall, the stock has great fundamentals and technical strength to stay in momentum.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Vimta Labs Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-01-24 Quarterly Results
2024-11-08 Quarterly Results
2024-07-17 Quarterly Results
2024-05-18 Audited Results & Final Dividend
2024-03-30 Amalgamation
Date Purpose Remarks
2022-06-18 FINAL Rs.2.00 per share(100%)Dividend
2021-06-28 FINAL Rs.2.00 per share(100%)Dividend
View More

Vimta Labs F&O

Vimta Labs Shareholding Pattern

36.76%
0.13%
3.81%
0.02%
25.09%
34.19%

About Vimta Labs

  • NSE Symbol
  • VIMTALABS
  • BSE Symbol
  • 524394
  • Managing Director
  • Ms. Harita Vasireddi
  • ISIN
  • INE579C01029

Similar Stocks to Vimta Labs

Vimta Labs FAQs

Vimta Labs share price is ₹845 As on 22 January, 2025 | 12:04

The Market Cap of Vimta Labs is ₹1878 Cr As on 22 January, 2025 | 12:04

The P/E ratio of Vimta Labs is 37.6 As on 22 January, 2025 | 12:04

The PB ratio of Vimta Labs is 5.5 As on 22 January, 2025 | 12:04

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23